Botox For Migraine: How Will The Market Size Up?
The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.
You may also be interested in...
Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.
With Botox now its biggest product, Allergan highlights moves to further the versatile drug’s expansion into new medical indications, as well as efforts to bolster the company’s traditional ophthalmic core, including advancing a pipeline candidate in the increasingly competitive wet-AMD field.
During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.